Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Busulfan 6 mg/ml concentrate for solution for infusion, THYMOGLOBULINE 5 mg/ml, poudre pour solution pour perfusion, Fludarabine Accord Healthcare 25 mg/ml solution Γ diluer pour solution injectable /pour perfusion
The George Institute
High-risk myeloΓ―d malignancies
1 trial -
Busulfan Koanaa 6 mg/ml Konzentrat zur Herstellung einer InfusionslΓΆsung, GRANOCYTE 34 Millions UI/ml, poudre et solvant pour solution injectable / perfusion, Autologous CD34+ cells transduced with lentiviral vector encoding the human beta-globin gene, Plerixafor Accord 20 mg/ml solution for injection
Fondazione Telethon ETS
transfusion-dependent beta-thalassemia
1 trial -
Byetta 10 micrograms solution for injection in pre-filled pen
The George Institute
Hypopituarism
1 trial -
Byfavo 20 mg powder for solution for injection
Disc Medicine
stress anxiety, anxiety
1 trial -
Byooviz 10 mg/ml solution for injection
Samsung Bioepis NL B.V.
Neovascular Age-Related Macular Degeneration (AMD), Macular Oedema Secondary to Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularization (mCNV)
1 trial -
CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coat
Fondazione Telethon ETS
bladder carcinoma of urothelial and non-urothelial histology
1 trial -
CABOMETYX 40 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion
The George Institute
Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma.
1 trial -
CALCIUM FOLINATE , MK-2870, -, -, PARACETAMOL , MK-1022, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CALCIUM LEVOFOLINATE , CAPECITABINE , -, MK-2870, FLUOROURACIL , OXALIPLATIN
Merck Sharp and Dohme
Gastroesophageal cancer
1 trial -
CAMPTO 20 mg/mL concentrate for solution for infusion, Futibatinib, Leucovorin-Teva 10 mg/ml Concentrate for Solution for Infusion, FLUOROURACIL, CISPLATIN, OXALIPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Taiho Pharma Netherlands B.V.
Solid Tumors
1 trial -
CAPECITABINE, CAPECITABINE, TRIPTORELIN, [177Lu]-NeoB solution for infusion, LEUPRORELIN, AAA503, GOSERELIN
Novartis Pharmaceuticals
Breast Cancer
1 trial -
CARBOCAINE 20 mg/ml, solution injectable
Pari Pharma GmbH
Ischemic stroke
1 trial -
CARBOPLATIN , ETOPOSIDE , ENZALUTAMIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, MK-7684A, DOCETAXEL , Belzutifan, Lenvatinib, Lenvatinib, PREDNISONE , ABIRATERONE , DEXAMETHASONE , Olaparib
Merck Sharp and Dohme
Metastatic Castration-Resistant Prostate Cancer
1 trial -
CARBOPLATIN , PACLITAXEL , NP137, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Lacuna Pharma Pty Ltd
Patiens with locally advanced/metastatic endometrial carcinoma or cervix carcinoma progressing/relapsing after at least one prior systemic chemotherapy.
1 trial -
CARBOPLATIN, BEVACIZUMAB, MK-4830, PACLITAXEL, KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL
Merck Sharp and Dohme
Primary peritoneal cancer/Fallopian tube cancer
1 trial -
CARBOPLATIN, Datopotamab deruxtecan, Inflectra 100 mg powder for concentrate for solution for infusion, ETOPOSIDE, CISPLATIN, Inflectra 100 mg powder for concentrate for solution for infusion, Inflectra 100 mg powder for concentrate for solution for infusion, Mycophenolate Mofetil Accord 250 mg capsules, Inflectra 100 mg powder for concentrate for solution for infusion, TAGRISSO 80 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for sol
AstraZeneca AB
Advanced Non-Small Cell Lung Cancer
1 trial -
CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion, Alunbrig 30 mg film-coated tablets, Alunbrig 180 mg film-coated tablets, Pemetrexed Viatris 25 mg/ml, solution Γ diluer pour perfusion
CERO THERAPEUTICS HOLDINGS, INC.
advanced ALK-positive non-small cell lung cancer
1 trial -
CBD Oral Solution
Jazz Pharmaceuticals Ireland Limited
Fragile X Syndrome
1 trial -
CBD Oral Solution (eCBD system Target)
Jazz Pharmaceuticals Ireland Limited
Fragile X Syndrome
1 trial -
CBD, ABILIFY 1 mg/ml oral solution, Aripiprazolo Aurobindo 15 mg compresse, ARIPIPRAZOLE , Composition (%w/V): Sesame oil, refined 90,00, Ethanol, anhydrous 7,91, Sucralose 0,05, DL-alfa-tocopheryl acetate 0,18, Raspberry flavor 0,02.
Fondazione Telethon ETS
Substance-Induced Psychosis
1 trial -
CETUXIMAB , MK-1084, MK-1084, MK-1084, KEYTRUDA 25 mg/mL concentrate for solution for infusion., CARBOPLATIN , PEMETREXED , MK-1084
Merck Sharp and Dohme
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC
1 trial -
CHF5993 pMDI (100) -152a, CHF5993 pMDI HFA-152a, Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution
Chiesi Farmaceutici S.p.A
Mild to moderate asthma
1 trial -
CISPLATIN, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CISPLATIN, FLUOROURACIL
Takeda
Solid Neoplasm
1 trial -
CISPLATIN, CARBOPLATIN, PACLITAXEL, PEMETREXED, LIBTAYO 350 mg concentrate for solution for infusion.
Talion
non-small cell lung cancer (NSCLC)
1 trial -
CISPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., GEMCITABINE
The George Institute
Extrahepatic cholangiocarcinoma (eCCA)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources